vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $120.9M, roughly 1.6× Sprout Social, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 12.9%). Sprout Social, Inc. produced more free cash flow last quarter ($9.9M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 11.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.
AXSM vs SPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $120.9M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | 77.6% |
| Operating Margin | -13.8% | -9.0% |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | 12.9% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $120.9M | ||
| Q3 25 | $171.0M | $115.6M | ||
| Q2 25 | $150.0M | $111.8M | ||
| Q1 25 | $121.5M | $109.3M | ||
| Q4 24 | $118.8M | $107.1M | ||
| Q3 24 | $104.8M | $102.6M | ||
| Q2 24 | $87.2M | $99.4M | ||
| Q1 24 | $75.0M | $96.8M |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-9.4M | ||
| Q2 25 | $-48.0M | $-12.0M | ||
| Q1 25 | $-59.4M | $-11.2M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-17.1M | ||
| Q2 24 | $-79.3M | $-16.9M | ||
| Q1 24 | $-68.4M | $-13.6M |
| Q4 25 | — | 77.6% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 77.7% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.1% | ||
| Q3 24 | — | 77.4% | ||
| Q2 24 | — | 77.5% | ||
| Q1 24 | — | 76.8% |
| Q4 25 | -13.8% | -9.0% | ||
| Q3 25 | -27.0% | -7.9% | ||
| Q2 25 | -24.5% | -11.0% | ||
| Q1 25 | -46.9% | -10.2% | ||
| Q4 24 | -61.1% | -12.8% | ||
| Q3 24 | -59.8% | -16.4% | ||
| Q2 24 | -89.5% | -16.6% | ||
| Q1 24 | -89.7% | -13.7% |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -8.1% | ||
| Q2 25 | -32.0% | -10.7% | ||
| Q1 25 | -48.9% | -10.3% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -16.6% | ||
| Q2 24 | -91.0% | -17.0% | ||
| Q1 24 | -91.1% | -14.0% |
| Q4 25 | $-0.55 | $-0.18 | ||
| Q3 25 | $-0.94 | $-0.16 | ||
| Q2 25 | $-0.97 | $-0.21 | ||
| Q1 25 | $-1.22 | $-0.19 | ||
| Q4 24 | $-1.54 | $-0.25 | ||
| Q3 24 | $-1.34 | $-0.30 | ||
| Q2 24 | $-1.67 | $-0.30 | ||
| Q1 24 | $-1.44 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $95.3M |
| Total DebtLower is stronger | — | $40.0M |
| Stockholders' EquityBook value | $88.3M | $203.4M |
| Total Assets | $689.8M | $523.1M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $95.3M | ||
| Q3 25 | $325.3M | $90.6M | ||
| Q2 25 | $303.0M | $101.5M | ||
| Q1 25 | $300.9M | $100.9M | ||
| Q4 24 | $315.4M | $86.4M | ||
| Q3 24 | $327.3M | $82.9M | ||
| Q2 24 | $315.7M | $80.9M | ||
| Q1 24 | $331.4M | $69.2M |
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $25.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $203.4M | ||
| Q3 25 | $73.7M | $194.1M | ||
| Q2 25 | $73.1M | $184.6M | ||
| Q1 25 | $53.2M | $175.3M | ||
| Q4 24 | $57.0M | $166.6M | ||
| Q3 24 | $92.9M | $158.1M | ||
| Q2 24 | $102.9M | $152.1M | ||
| Q1 24 | $144.0M | $147.3M |
| Q4 25 | $689.8M | $523.1M | ||
| Q3 25 | $669.3M | $481.4M | ||
| Q2 25 | $639.8M | $422.9M | ||
| Q1 25 | $596.7M | $424.7M | ||
| Q4 24 | $568.5M | $428.3M | ||
| Q3 24 | $561.5M | $388.8M | ||
| Q2 24 | $548.2M | $393.6M | ||
| Q1 24 | $545.7M | $389.9M |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $10.9M |
| Free Cash FlowOCF − Capex | $-18.7M | $9.9M |
| FCF MarginFCF / Revenue | -9.6% | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $39.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $10.9M | ||
| Q3 25 | $1.0M | $9.3M | ||
| Q2 25 | $-32.4M | $5.1M | ||
| Q1 25 | $-43.4M | $18.1M | ||
| Q4 24 | $-26.2M | $4.1M | ||
| Q3 24 | $-18.6M | $9.0M | ||
| Q2 24 | $-30.1M | $2.1M | ||
| Q1 24 | $-53.5M | $11.2M |
| Q4 25 | $-18.7M | $9.9M | ||
| Q3 25 | $988.0K | $8.5M | ||
| Q2 25 | $-32.4M | $4.2M | ||
| Q1 25 | $-43.7M | $16.7M | ||
| Q4 24 | $-26.2M | $3.3M | ||
| Q3 24 | $-18.7M | $8.5M | ||
| Q2 24 | $-30.2M | $1.6M | ||
| Q1 24 | $-53.6M | $10.1M |
| Q4 25 | -9.6% | 8.2% | ||
| Q3 25 | 0.6% | 7.4% | ||
| Q2 25 | -21.6% | 3.7% | ||
| Q1 25 | -36.0% | 15.3% | ||
| Q4 24 | -22.1% | 3.0% | ||
| Q3 24 | -17.9% | 8.3% | ||
| Q2 24 | -34.6% | 1.6% | ||
| Q1 24 | -71.4% | 10.4% |
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 1.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
